Skip to main content

Zepatier FDA Approval History

FDA Approved: Yes (First approved January 28, 2016)
Brand name: Zepatier
Generic name: elbasvir and grazoprevir
Dosage form: Tablets
Company: Merck
Treatment for: Hepatitis C

Zepatier (elbasvir and grazoprevir) is a once-daily, single tablet, NS5A replication complex inhibitor and NS3/4A protease inhibitor combination for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections.

Development timeline for Zepatier

DateArticle
Jan 28, 2016Approval FDA Approves Zepatier (elbasvir and grazoprevir) for Chronic Hepatitis C Genotypes 1 and 4
Jul 28, 2015Merck Announces FDA Acceptance of NDA for Grazoprevir/Elbasvir for Chronic Hepatitis C Genotypes 1, 4 and 6 Infection
May 28, 2015Merck Submits NDA for Grazoprevir/Elbasvir for Chronic Hepatitis C Genotypes 1, 4, and 6 Infection

See also

Zepatier (elbasvir and grazoprevir) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer